These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 9489524)

  • 1. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
    Créange A; Bélec L; Clair B; Degos JD; Raphaël JC; Gherardi RK
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):162-5. PubMed ID: 9489524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating the immune response in demyelinating diseases.
    Hughes R
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148. PubMed ID: 9489519
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
    Rees JH
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148-9. PubMed ID: 9489520
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased serum concentrations of transforming growth factor-β1 (TGF-β1) in patients with Guillain-Barré syndrome.
    Chang KH; Lyu RK; Ro YS; Chen YC; Ro LS; Chang HS; Huang CC; Liao MF; Wu YR; Kuo HC; Chu CC; Chen CM
    Clin Chim Acta; 2016 Oct; 461():8-13. PubMed ID: 27450064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.
    Sharief MK; Ingram DA; Swash M; Thompson EJ
    Neurology; 1999 Jun; 52(9):1833-8. PubMed ID: 10371531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.
    Sindern E; Schweppe K; Ossege LM; Malin JP
    J Neurol; 1996 Mar; 243(3):264-8. PubMed ID: 8936357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic approaches to Guillain-Barré syndrome.
    Pritchard J
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2307-18. PubMed ID: 11060808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method.
    Kesici S; Tanyıldız M; Yetimakman F; Bayrakci B
    J Child Neurol; 2019 Apr; 34(5):277-283. PubMed ID: 30696330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome.
    Exley AR; Smith N; Winer JB
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1118-20. PubMed ID: 8089682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
    Visser LH; van der Meché FG; Meulstee J; van Doorn PA
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
    Hartung HP; Reiners K; Schmidt B; Stoll G; Toyka KV
    Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
    Weinstein R
    J Clin Apher; 1995; 10(3):150-7. PubMed ID: 8582898
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
    van der Meché FG; Schmitz PI
    N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome.
    Ann Neurol; 1987 Dec; 22(6):753-61. PubMed ID: 2893583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome.
    Ansar V; Valadi N
    Prim Care; 2015 Jun; 42(2):189-93. PubMed ID: 25979580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin.
    Buzzigoli SB; Genovesi M; Lambelet P; Logi C; Raffaelli S; Cattano D
    Anaesth Intensive Care; 2010 Mar; 38(2):387-9. PubMed ID: 20369779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunotherapy of Guillain-Barré syndrome.
    Restrepo-Jiménez P; Rodríguez Y; González P; Chang C; Gershwin ME; Anaya JM
    Expert Opin Biol Ther; 2018 Jun; 18(6):619-631. PubMed ID: 29681203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients.
    Hughes RA; Hadden RD; Rees JH; Swan AV
    Brain; 1998 Apr; 121 ( Pt 4)():767-9. PubMed ID: 9577400
    [No Abstract]   [Full Text] [Related]  

  • 20. Whole blood tumor necrosis factor-alpha production and its relation to systemic concentrations of interleukin 4, interleukin 10, and transforming growth factor-beta1 in multiply injured blunt trauma victims.
    Majetschak M; Börgermann J; Waydhas C; Obertacke U; Nast-Kolb D; Schade FU
    Crit Care Med; 2000 Jun; 28(6):1847-53. PubMed ID: 10890631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.